SG146622A1 - Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer - Google Patents
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancerInfo
- Publication number
- SG146622A1 SG146622A1 SG200806620-1A SG2008066201A SG146622A1 SG 146622 A1 SG146622 A1 SG 146622A1 SG 2008066201 A SG2008066201 A SG 2008066201A SG 146622 A1 SG146622 A1 SG 146622A1
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- diagnosis
- cancer
- proteins
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03090307 | 2003-09-18 | ||
| US51207803P | 2003-10-20 | 2003-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG146622A1 true SG146622A1 (en) | 2008-10-30 |
Family
ID=37657558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200806620-1A SG146622A1 (en) | 2003-09-18 | 2004-09-20 | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090252721A1 (fr) |
| EP (2) | EP1673470A2 (fr) |
| JP (1) | JP2007521015A (fr) |
| CN (1) | CN1902326A (fr) |
| AU (1) | AU2004272747A1 (fr) |
| BR (1) | BRPI0414446A (fr) |
| CA (1) | CA2539490A1 (fr) |
| IL (1) | IL174047A0 (fr) |
| SG (1) | SG146622A1 (fr) |
| WO (1) | WO2005026735A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006093337A1 (fr) * | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | Agent préventif/thérapeutique pour le cancer |
| US7897583B2 (en) | 2005-05-24 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to PTPRU |
| WO2007058536A1 (fr) * | 2005-11-16 | 2007-05-24 | Pantarhei Bioscience B.V. | Composition pharmaceutique destinee au traitement ou a la prevention du cancer des ovaires |
| US20100028335A1 (en) * | 2007-02-02 | 2010-02-04 | Novartis Ag | Compositions and Methods to Treat Bone Related Disorders |
| JP2010527633A (ja) * | 2007-05-25 | 2010-08-19 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Ｔｏｌｌ様受容体３モジュレーター及びその使用 |
| CN102395682B (zh) * | 2007-09-06 | 2015-09-30 | 生物治疗诊断股份有限公司 | 肿瘤分级和癌症预后 |
| US8158373B2 (en) * | 2008-03-25 | 2012-04-17 | Case Western Reserve University | Method of detecting cancer and evaluating cancer prognosis |
| WO2010056993A2 (fr) * | 2008-11-14 | 2010-05-20 | Emory University | Biomarqueurs du cancer de la prostate pour prédire la récurrence et le potentiel métastasique |
| US9492472B2 (en) | 2008-12-23 | 2016-11-15 | Case Western Reserve University | Compositions and methods of treating cancer |
| WO2011008631A2 (fr) | 2009-07-16 | 2011-01-20 | Omnova Solutions Inc. | Compositions de revêtement protecteur |
| EP2975399B1 (fr) | 2010-09-15 | 2022-05-11 | Almac Diagnostic Services Limited | Test de diagnostic moléculaire pour le cancer |
| EP2809800A1 (fr) | 2012-01-30 | 2014-12-10 | VIB vzw | Moyens et procédé pour le diagnostic et le traitement de la maladie d'alzheimer |
| AU2013231972B2 (en) * | 2012-03-14 | 2018-03-22 | Salk Institute For Biological Studies | Adenoviral tumor diagnostics |
| JP6327662B2 (ja) * | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| WO2016080830A2 (fr) * | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Procédé immunothérapeutique pour le traitement du cancer du pancréas |
| CN109646685A (zh) * | 2017-10-12 | 2019-04-19 | 北京医院 | stomatin蛋白及其编码基因在肺癌诊断治疗中的应用 |
| CN111394370B (zh) * | 2020-03-03 | 2022-03-25 | 华南农业大学 | 一种猪RagA基因及其应用 |
| AU2021241355A1 (en) | 2020-03-23 | 2022-10-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| CN114540349A (zh) * | 2020-11-27 | 2022-05-27 | 中国科学院分子细胞科学卓越创新中心 | 结合yb-1蛋白的核酸分子 |
| AU2022348995A1 (en) * | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54117459A (en) | 1978-01-20 | 1979-09-12 | Glaxo Group Ltd | Novel lactam compound |
| US4849338A (en) | 1982-07-16 | 1989-07-18 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4843000A (en) | 1979-12-26 | 1989-06-27 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4520110A (en) | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4542104A (en) | 1983-04-06 | 1985-09-17 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Phycobiliprotein fluorescent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB9705949D0 (en) | 1997-03-21 | 1997-05-07 | Electrophoretics International | Diagnosis of tumours and other abnormalities of body cells |
| US6197543B1 (en) * | 1997-10-28 | 2001-03-06 | Incyte Pharmaceuticals, Inc. | Human vesicle membrane protein-like proteins |
| US6902898B2 (en) * | 1998-11-16 | 2005-06-07 | National Institute Of Advanced Industrial Science And Technology | Human derived bradeion proteins, DNA coding for the proteins, and uses thereof |
| EP1033404A1 (fr) * | 1999-01-29 | 2000-09-06 | F. Hoffmann-La Roche Ag | Gène dont l'expression est réduite dans les cellules de mélanome métastatiques humaines |
| US6228392B1 (en) | 1999-04-29 | 2001-05-08 | Gene Tools, Llc | Osmotic delivery composition, solution, and method |
| EP1265582A2 (fr) * | 1999-09-29 | 2002-12-18 | Human Genome Sciences, Inc. | Polynucleotides et polypeptides associes au colon et au cancer du colon |
| US20030104413A1 (en) * | 2000-07-14 | 2003-06-05 | Tang Y. Tom | Novel Nucleic acids and polypeptides |
| US20030108926A1 (en) * | 2000-03-15 | 2003-06-12 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| CA2411278A1 (fr) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer du colon |
| JP2004512029A (ja) * | 2000-08-16 | 2004-04-22 | カイロン コーポレイション | ヒト遺伝子および遺伝子発現産物 |
| US20030134283A1 (en) * | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| US20020160382A1 (en) * | 2000-10-11 | 2002-10-31 | Lasek Amy W. | Genes expressed in colon cancer |
| AU2002343443A1 (en) * | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| EP1308459A3 (fr) * | 2001-11-05 | 2003-07-09 | Research Association for Biotechnology | Séquences d'ADN complementaires pleine longueur |
| EP1560597A4 (fr) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | Genes exprimes de maniere differenciee impliques dans le cancer, polypeptides codes par ces genes, et methodes d'utilisation des genes |
-
2004
- 2004-09-20 EP EP04765615A patent/EP1673470A2/fr not_active Ceased
- 2004-09-20 JP JP2006526617A patent/JP2007521015A/ja active Pending
- 2004-09-20 US US10/571,167 patent/US20090252721A1/en not_active Abandoned
- 2004-09-20 WO PCT/EP2004/010780 patent/WO2005026735A2/fr active Application Filing
- 2004-09-20 AU AU2004272747A patent/AU2004272747A1/en not_active Abandoned
- 2004-09-20 SG SG200806620-1A patent/SG146622A1/en unknown
- 2004-09-20 BR BRPI0414446-5A patent/BRPI0414446A/pt not_active IP Right Cessation
- 2004-09-20 CA CA002539490A patent/CA2539490A1/fr not_active Abandoned
- 2004-09-20 CN CNA200480034085XA patent/CN1902326A/zh active Pending
- 2004-09-20 EP EP08163922A patent/EP2050827A3/fr not_active Withdrawn
-
2006
- 2006-03-01 IL IL174047A patent/IL174047A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0414446A (pt) | 2006-11-14 |
| IL174047A0 (en) | 2006-08-01 |
| JP2007521015A (ja) | 2007-08-02 |
| WO2005026735A3 (fr) | 2005-11-03 |
| EP2050827A2 (fr) | 2009-04-22 |
| CN1902326A (zh) | 2007-01-24 |
| CA2539490A1 (fr) | 2005-03-24 |
| EP2050827A3 (fr) | 2009-09-02 |
| AU2004272747A1 (en) | 2005-03-24 |
| WO2005026735A2 (fr) | 2005-03-24 |
| EP1673470A2 (fr) | 2006-06-28 |
| US20090252721A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG146622A1 (en) | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer | |
| Jiang et al. | Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells | |
| Sager et al. | Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene | |
| Ishibashi et al. | Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and β subunit of the high-affinity IgE receptor | |
| Schmid et al. | The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells | |
| Chung et al. | CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation | |
| Izumoto et al. | Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion | |
| Lin et al. | Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines | |
| Catusse et al. | Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia | |
| WO2005100998A3 (fr) | Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer | |
| Xiang et al. | Isolation of complementary DNA encoding K-cadherin, a novel rat cadherin preferentially expressed in fetal kidney and kidney carcinoma | |
| Knutti et al. | Soluble extracellular matrix metalloproteinase inducer (EMMPRIN, EMN) regulates cancer‐related cellular functions by homotypic interactions with surface CD 147 | |
| EA200600055A1 (ru) | Агонисты рецептора меланокортина 4 (мк4 ) и их применение | |
| BR0306973A (pt) | Anticorpos anti-igf-ir e respectivas aplicações | |
| CY1106991T1 (el) | Αντιπολλαπλασιαστικη δραση ολιγονουκλεοτιδιων πλουσιων σε g και μεθοδος χρησιμοποιησης αυτων για την προσδεση σε νουκλεολινη | |
| AU2006296171A1 (en) | Hepatocyte growth factor receptor splice variants and methods of using same | |
| Imai et al. | Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death | |
| Southby et al. | Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein | |
| Twito et al. | Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression | |
| Rybczynska et al. | MDR1 causes resistance to the antitumour drug miltefosine | |
| WO2002088750A3 (fr) | Proteines, genes et leur utilisation dans le cadre du diagnostic et du traitement du cancer du sein | |
| Laisney et al. | Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops | |
| Haines et al. | The NLRR gene family and mouse development: Modified differential display PCR identifies NLRR-1 as a gene expressed in early somitic myoblasts | |
| CA2319715A1 (fr) | Proteine de resistance aux medicaments contre le cancer du sein (bcrp) et adn codant cette proteine | |
| Moiseeva et al. | CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion |